NCCN Guidelines® Insights - Breast Cancer, Version 4.2023
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer address all aspects of management for breast cancer. The treatment landscape of metastatic breast cancer is evolving constantly. The therapeutic strategy takes into consideration tumor biology, biomarkers, and other clinical factors. Due to the growing number of treatment options, if one option fails, there is usually another line of therapy available, providing meaningful improvements in survival. This NCCN Guidelines Insights report focuses on recent updates speciﬁc to systemic therapy recommendations for patients with stage IV (M1) disease.
This activity is designed to meet the educational needs of oncologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to the NCCN Guidelines for Breast Cancer
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Breast Cancer
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Individuals Who Provided Content Development and/or Authorship Assistance
The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.
Jame Abraham, MD, Panel Member
Helen Chew, MD, Panel Member
Mary A. Dwyer, MS, CGC, Senior Director, Guidelines Operations, NCCN
Rashmi Kumar, PhD, Senior Director, Clinical Information Operations, NCCN
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
William J. Gradishar, MD, Panel Chair, has disclosed serving as a scientific advisor for AstraZeneca Pharmaceuticals LP, Biotheranostics, Daiichi-Sankyo Co., Eli Lilly and Company, ImmunoGen, Inc., MacroGenics, Puma Biotechnology, and Seattle Genetics, Inc.; and receiving honoraria from AstraZeneca Pharmaceuticals LP, Biotheranostics, Daiichi-Sankyo Co., and ImmunoGen, Inc.
Anthony D. Elias, MD, Panel Member, has disclosed receiving grant/research support from Astellas Pharma US, Inc., BioAtla, C4 Therapeutics, Epizyme, Inc., Fosun Orinove PharmaTech, Inc., ImmuneOnco Biopharmaceuticals, Infinity Pharmaceuticals, Inc., PTC Therapeutics, Quantum Leap Healthcare Collaborative, and Zenshine Pharmaceuticals Inc.
Rachel C. Jankowitz, MD, Panel Member, has disclosed serving as a scientific advisor to Biotheranostics.
Hope S. Rugo, MD, Panel Member, has disclosed receiving grant/research support from Astellas Pharma US, Inc., AstraZeneca Pharmaceuticals LP, Daiichi-Sankyo Co., Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, OBI Pharma, Inc., Pionyr Immunotherapeutics Inc., Pfizer, Inc., Roche Laboratories, Inc., Sermonix Pharmaceuticals, Taiho Pharmaceuticals Co., Ltd., and Veru Inc.; serving as a scientific advisor for Blueprint Medicines, Napo Pharmaceuticals, Inc., Puma Biotechnology, and Scorpion Therapeutics; and receiving consulting fees from Blueprint Medicines, Napo Pharmaceuticals, Inc., Puma Biotechnology, and Scorpion Therapeutics.
Hatem Soliman, MD, Panel Member, has disclosed receiving consulting fees from AstraZeneca Pharmaceuticals LP, Novartis Pharmaceuticals Corporations, Puma Biotechnology, and SeaGen; receiving grant/research support from Amgen Inc.; and serving in a product/speakers bureau for Merck & Co., Inc.
Kari B. Wisinksi, MD, Panel Member, has disclosed receiving grant/research support from Context Therapeutics, Novartis Pharmaceuticals Corporation, Pfizer Inc., and Puma Biotechnology; and receiving consulting fees from Novartis Pharmaceuticals Corporation, Pfizer Inc., sanofi-aventis U.S., and Stemline Therapeutics Inc.
Kay Yeung, MD, Panel Member, has disclosed receiving grant/research support from BioFluidica, Dantari, Inc., Gilead Sciences, Inc., Immunomedics, Inc., Regeneron Pharmaceuticals, SeaGen, and Zymeworks.
NCCN Staff Disclosures
None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: JA4008196-0000-23-006-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until June 10, 2024. PAs should only claim credit commensurate with the extent of their participation.
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation